To determine if PCDT should be routinely used to treat proximal DVT, to establish if PCDT prevents post thrombotic syndrome (PTS) and improves health-related quality of life with acceptable safety and costs. The rationale for performing this study is based upon (a) a major burden of PTS on DVT patients and the US health system; (b) the association between rapid clot lysis and prevention of PTS; (c) the proven ability of rt-PA (study drug) to dissolve venous thrombosis in proximal DVT; (d) recent advances in PCDT methods and (e) the major clinical controversy if PCDT should be routinely used.
Impact
This study is expected to catalyze a fundamental change in DVT practice towards routine, first-line use of PCDT in the treatment of proximal DVT. If PDCT proves ineffective or insufficiently safe, this finding will reduce or eliminate the use of a potentially risky and expensive procedure. The study is endorsed by the Society of Interventional Radiologists, the American Venous Forum, the May 2006 American Surgeon General's DVT Workshop.
Student Experience
No student involvement.
Countries
Canada, United States of America
Impact
Research
Institutional Partner(s)
NIH - NHLBI, Washington University
Community Partner(s)
Industry Partner(s)
Key Outcomes
Publications
Sponsorship
Foreign
Sponsorship Details
Study funded by the National Institute of Health, National Heart Lung and Blood Institute (NHLBI)
